Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 7/20 | 0.36 |
| ▸ | MAP4K3 | Q8IVH8 | 5/20 | 0.36 |
| ▸ | EGFR | P00533 | 8/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886266 | 0.94 | IRAK4 (0.37) | IRAK4JAK3MAP4K1MAP4K3EGFR | |
| SCHEMBL3881367 | 0.94 | IRAK4 (0.43) | IRAK4JAK3MAP4K1MAP4K3EGFR | |
| SCHEMBL3883496 | 0.89 | EGFR (0.34) | IRAK4JAK3MAP4K1EGFRFGFR2 | |
| SCHEMBL3889429 | 0.89 | EGFR (0.34) | IRAK4JAK3MAP4K1EGFRFGFR2 | |
| SCHEMBL3996368 | 0.88 | EGFR (0.35) | IRAK4JAK3EGFRFGFR2MAPK1 | |
| SCHEMBL3892410 | 0.83 | IRAK4 (0.43) | IRAK4JAK3EGFRPDE4B | |
| SCHEMBL3883288 | 0.82 | EGFR (0.34) | IRAK4MAP4K1EGFR | |
| SCHEMBL3884015 | 0.80 | EGFR (0.40) | EGFRPDE4B | |
| SCHEMBL14452559 | 0.78 | IRAK4 (0.38) | IRAK4JAK3MAP4K1MAP4K3EGFR | |
| SCHEMBL3881918 | 0.77 | CASR (0.38) | IRAK4JAK3EGFRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771443-B1 | QUINOLINE THIAZOLINONES WITH CDK-1 ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | claimed |
| US-7250515-B2 | Thiazolinone 3,4-disubstituted quinolines | HOFFMAN-LA ROCHE INC. (US) | 2007-07-31 | — | — | US | claimed |
| US-20060004046-A1 | Thiazolinone 3,4-disubstituted quinolines | CHEN LI | 2006-01-05 | — | — | US | claimed |
| EP-1771443-B1 | QUINOLINE THIAZOLINONES WITH CDK-1 ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-7250515-B2 | Thiazolinone 3,4-disubstituted quinolines | HOFFMAN-LA ROCHE INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20060004046-A1 | Thiazolinone 3,4-disubstituted quinolines | CHEN LI | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004046-A1 | Thiazolinone 3,4-disubstituted quinolines | CDK1, CDK17, CDK14 | IRAK4 2540/4885JAK3 548/4885MAP4K1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.